Article
Are intra-articular steroid injections effective in symptomatic knee OA? Do they accelerate cartilage loss? Does weight less actually help? Do we have DMARDs for knee OA? Insights from 2020 ACR Convergence.
All News
Article
Dr. Jack Cush reviews a few more ACR 2020 abstracts and presents a new plan to learn or take in ACR20 content.
Article
Portland-based Dr. Kevin Winthrop from OHSU discusses Saturday ACR 2020 posters #0623 and #0629 related to COVID-19 and rheumatic disease patients.
Article
Dr. Jack Cush reviews this past week at Virtual ACR 2020 - highlights from the meeting and his view of best/newest studies.
What will people remember or talk about from ACR 2020?
Article
Check out our many podcasts from the ACR 2020 meeting - listen in for faculty reports and overviews. You can also find the RheumNow podcast on Apple Podcast, Apple Car Play, Android Auto or where ever you prefer to listen.
Listen here:
Article
Here are my highlights from day four, Monday, of the ACR 2020 Convergence.
Vaccine Immunogenicity with Tofacitinib
Article
Check out our many podcasts from the ACR 2020 meeting - listen in for faculty reports and overviews. You can also find the RheumNow podcast on Apple Podcast, Apple Car Play, Android Auto or where ever you prefer to listen.
Listen here:
Article
Check out our many podcasts from the ACR 2020 meeting - listen in for faculty reports and overviews. You can also find the RheumNow podcast on Apple Podcast, Apple Car Play, Android Auto or where ever you prefer to listen.
Listen here:
Article
Check out our many podcasts from the ACR 2020 meeting - listen in for faculty reports and overviews. You can also find the RheumNow podcast on Apple Podcast, Apple Car Play, Android Auto or where ever you prefer to listen.
Listen here:
Article
The Annual Review of Best ACR 2020 abstracts featuring Drs. Cush and Kavanaugh filmed on the last day of Virtual ACR 2020 Nov. 9, 2020. Watch now!
Dr. John Cush
Tweet
Dr. Janet Pope ( @Janetbirdope) reviews abstract #1001 presented at #ACR20 on risk of skin cancer with methotrexate.
https://t.co/N0JelI6K5p https://t.co/n07HoO5j3y
Dr. John Cush
Tweet
#BestACR20Tweets
RT @ejdein1:Abst#2001: Heme changes on MTX? CIRT trial (non-rheumatic pts): Low-dose MTX (15-20mg/w): 2 line cytopenia uncommon (4%), pancytopenia rare (0.5%), Hb decrease 0.4 g/dL but WBC, plt unchanged. Reassuring large pop study shows tolerance of MTX #ACR20
Dr. John Cush
Tweet
#BestACR20Tweets
RT @ejdein1 :Abst#2001: Heme changes on MTX? CIRT trial (non-rheumatic pts): Low-dose MTX (15-20mg/w):2 line cytopenia uncommon (4%), pancytopenia rare (0.5%), Hb decrease 0.4 g/dL but WBC, plt unchanged. Reassuring large pop study shows tolerance of MTX #ACR20
Dr. John Cush
Tweet
#BestACR20Tweets
RT @MeralElRamahiMD : When do you think we are going to get a DMARD for OA? 50% or more over age 60 will have osteoarthritis, yet we are yet to discover a promising disease modifying therapy. #ACR20 @ElaineHusniMD
Dr. John Cush
Tweet
What is the SEAMless transition from combination Etanercept to Methotrexate? with Dr. Jonathan Kay #ACR20
https://t.co/58raeaE8Mr https://t.co/FUIidcoy4I
Dr. John Cush
Tweet
SEAM-RA Trial: Dr. Jeff Curtis ( @RADoctor) discusses abstract # 0939 that looked at whether RA patients at or close to remission should continue taking their combination therapy, as presented at #ACR20
https://t.co/2yMyj4BKs1 https://t.co/2gqJM4EKpG
Dr. John Cush
Tweet
Dr. David Liew ( @drdavidliew) reviews abstracts #0431 on HCQ and QTc Prolongation as presented at #ACR20.
https://t.co/vbqf7UNzVY https://t.co/qBCqFqYQCo
Dr. John Cush
Tweet
Methotrexate Induced Liver Fibrosis: Dr. Sheila Reyes ( @RHEUMarampa) discusses abstract #0205 presented Friday at the #ACR20 annual meeting.
https://t.co/P80WIGXOPg https://t.co/xEAuxSqIQv
Meral K. El Ramahi, MD
Tweet
Inadequate response to MTX, what next?
“Are you forward thinking or are you stuck in the past? Conceptually it is just amazing that you can take a PO tablet as potent as a TNF or IL6 blocker... & the side effects are not so appalling.”—Dr. GreggSilverman. @RheumNow
Meral K. El Ramahi, MD
Tweet
When do you think we are going to get a DMARD for OA? 50% or more over age 60 will have osteoarthritis, yet we are yet to discover a promising disease modifying therapy. #ACR20 @RheumNow @ElaineHusniMD
